IL6 and type 1 diabetes mellitus: The clinical trial EXTEND (clinical trial NCT02293837) investigated whether blocking IL-6 signaling (tocilizumab, anti-IL-6 receptor antibody) can provide improved beta-cell function in T1D patients.